Read More

FDA Granted Mesoblast Regenerative Medicine Advanced Therapy Designation granted For Rexlemestrocel-L In Chronic Low Back Pain

Mesoblast Limited (ASX:MSB; Nasdaq:MESO) today announced that the United States Food and Drug Administration's (FDA) Office of Tissues and Advanced Therapies (OTAT) has granted Regenerative Medicine Advanced Therapy (RMAT) designation for rexlemestrocel-L in the treatment of chronic low back pain (CLBP) associated with disc degeneration, in combination with hyaluronic acid (HA) as delivery agent

MESO

Read More

Genetic Technologies Announced New Publication Highlights geneType’s ability to Detect Breast Cancer Earlier and Provide Data for Risk Stratification

Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, "Company","GTG") is pleased to announce the publication of a new research paper in the peer-reviewed journal Breast Cancer Research and Treatment. Highlights: • GeneType outperforms 5-year and remaining lifetime risk prediction compared to the commonly used clinical models Gail and IBISv7, respectively.

GENE

Read More

Lixiang Education Regains Compliance with Nasdaq Listing Requirement

Lixiang Education Holding Co., Ltd (the "Company") received a letter from the Listing Qualifications Department of The Nasdaq Global Market ("Nasdaq") on February 6, 2023, confirming that the Company has regained compliance with the Listing Rule 5450(a)(2) (the "Rule"), which requires the Company to have at least 400 public holders for continued listing on the Nasdaq Global Market.

LXEH